|
|
|
This is the preliminary program for the 2009 Joint Statistical
Meetings in Washington, DC.
|
|
|
The views expressed here are those of the individual authors and not necessarily those of the ASA or its board, officers, or staff. Back to main JSM 2009 Program page |
= Applied Session,
= Theme Session,
= Presenter| 175 | Mon, 8/3/09, 12:30 PM - 1:50 PM | CC-Ballroom South Prefunction |
| Biopharmaceutical Section Roundtables with Lunch (fee event) - Roundtables - with Lunch | ||
|
Biopharmaceutical Section |
||
| Organizer(s): Dionne Price, FDA | ||
| ML08: |
Pooling versus No Pooling of Safety Data from Clinical Trials —  Vipin Arora, Takeda Pharmaceuticals
|
|
| ML09: |
Data-Monitoring Committees: What Is the Scope of the Information the DMC Can Review? — Dennis W. King, STATKING Consulting, Inc.
|
|
| ML10: |
Statistical Analyses of HIV Drug Resistance — David B. Hall, Boehringer Ingelheim Pharmaceuticals, Inc.
|
|
| ML11: |
Design and Analysis Issues for FDA Medical Device Submissions — Gary Kamer, FDA
|
|
| ML12: |
Randomization Strategies in Multicenter Trials — Olga M. Kuznetsova, Merck & Co., Inc.
|
|
| ML13: |
The Use of Decision Analysis in Clinical Trials — Telba Irony, FDA
|
|
|
JSM 2009
For information, contact jsm@amstat.org
or phone (888) 231-3473. If you have questions about the Continuing Education program,
please contact the Education Department. |